Equities

Acrux Ltd

Acrux Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.065
  • Today's Change0.00 / 0.00%
  • Shares traded50.02k
  • 1 Year change+18.18%
  • Beta1.2413
Data delayed at least 20 minutes, as of May 03 2024 00:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto(estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.

  • Revenue in AUD (TTM)14.46m
  • Net income in AUD-709.00k
  • Incorporated1998
  • Employees43.00
  • Location
    Acrux Ltd103-113 Stanley St, West MelbourneMELBOURNE 3003AustraliaAUS
  • Phone+61 38379-0100
  • Fax+61 38379-0101
  • Websitehttps://www.acrux.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Adalta Ltd3.56m-5.04m14.38m----5.86--4.04-0.0129-0.01290.00920.00460.5491--4.72---77.76-67.77-195.09-103.16-----141.60-160.72---57.860.4533--28.1811.1719.96---7.47--
Oncosil Medical Ltd355.30k-11.71m14.88m2.00--2.56--41.89-0.0081-0.00810.00020.0020.0506--7.88---166.55-57.65-234.81-64.83-426.96---3,295.08-473.02---68.930.0256---59.92-37.72-5.74--40.13--
Medlab Clinical Ltd943.67k-6.78m15.07m14.00------15.97-2.97-2.970.41330.56040.13012.2510.35---88.67-55.07-127.20-69.7590.4552.86-681.73-335.431.67-217.550.00---28.90-29.8318.55---30.00--
Nyrada Inc3.08m-4.98m16.15m----3.07--5.24-0.0319-0.03190.01980.02940.3983-------64.37-64.90-71.93-84.66-----161.62-380.62---15,086.390.00--42.54229.09-96.52------
Patrys Ltd1.70m-5.12m16.46m15.00--3.28--9.71-0.0025-0.00250.00080.00240.1978--0.5828---59.77-43.96-68.99-47.06-----302.26-230.44----0.00---14.4540.52-4.15------
Amplia Therapeutics Ltd1.87m-4.46m16.84m1.00--0.8389--9.01-0.0224-0.02240.00940.07390.0949--0.7018---22.64-25.27-26.24-26.78-----238.69-342.26----0.1318---42.1012.31-71.30--31.88--
Argent BioPharma Ltd1.32m-17.02m17.21m----10.23--12.99-3.32-3.320.10030.03720.08130.70781.58---105.32-111.29-345.98-171.0521.8732.52-1,295.20-632.420.6561-24.850.4104---28.4147.31-2.34---16.20--
Noxopharm Ltd3.90m-12.13m17.53m1.00k--2.67--4.49-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
LTR Pharma Ltd-100.00bn-100.00bn17.60m----5.55----------0.0451----------------------------0.00---100.00---41.65------
Syntara Ltd9.83m-14.26m17.91m107.00--1.99--1.82-0.0197-0.01720.01360.00750.4421.582.22---64.13-27.33-97.76-34.2381.6988.37-145.11-61.991.75-262.590.0674--23.60-18.30-486.78---31.06--
Auscann Group Holdings Ltd2.05m-9.44m17.95m27.00------8.76-0.0213-0.02170.00430.01620.1674--5.35---77.15-39.85-78.72-40.73100.59---460.74-925.91---23.160.00--13.8851.3757.10------
Radiopharm Theranostics Ltd0.00-46.82m18.07m----0.6134-----0.1343-0.13430.000.06520.00-------63.11---77.85-------------7.480.00-------13.78------
Algorae Pharmaceuticals Ltd84.10k-2.25m18.55m----5.12--220.57-0.0015-0.00150.000060.00220.0245--1.79---65.51-46.12-70.91-53.52-----2,678.04-591.05---136.750.00--1,132.26-44.06-7.68------
Acrux Ltd14.46m-709.00k18.90m43.00--3.34--1.31-0.0024-0.00240.05020.01951.29--4.86---6.34-39.91-9.21-46.0072.38---4.90-132.53----0.2861--133.7428.2992.23---16.66--
Rhythm Biosciences Ltd157.67k-8.63m20.17m----14.90--127.93-0.0386-0.03860.00070.00550.0263--1.81---144.00-106.11-169.71-125.51-1,899.74-1,210.71-5,473.20-6,642.262.04--0.0304--814.1828.776.55---20.43--
Immuron Ltd3.58m-3.88m22.80m6.00--1.30--6.37-0.017-0.0170.01570.07690.16640.64687.92596,106.70-18.06-27.48-19.86-29.5880.8777.52-108.52-296.647.79-2.850.0023--135.85-13.34-32.66--3.27--
Data as of May 03 2024. Currency figures normalised to Acrux Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.